What Happened?
Aprogen secured a patent in Brazil on September 17, 2025, for its anti-CD47 antibody and its use in cancer treatment. This antibody holds potential for treating various blood cancers, including acute myeloid leukemia.
Why is it Important?
This patent validates Aprogen’s core technological capabilities and marks a significant step in expanding its innovative drug pipeline. The CD47-targeted antibody, related to the immune checkpoint inhibition mechanism, offers potential for treating various blood and solid cancers. Upon successful development of dual-antibody technology, mass production is planned at Aprogen Biologics’ Osong plant, with plans for domestic and international market entry through collaborations with global pharmaceutical companies.
What’s Next?
- Positive Aspects: New revenue streams, driving growth in the biopharmaceutical business, synergy with CDMO business, global market entry, and business diversification.
- Potential Risks: Uncertainties in clinical trials and product approvals, high development costs and time, terms of technology transfer/joint development, and intensified market competition.
While the patent acquisition itself will not have a direct financial impact in the short term, it could positively affect stock prices by raising market expectations. In the mid to long term, the success of new drug development and commercialization will be the key factor determining corporate value.
What Should Investors Do?
Investors should continuously monitor relevant news, such as clinical trial progress, R&D updates, and partnership agreements. Careful investment decisions should be made considering the potential risks.